HPCM
MRSN

Hunter Perkins Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Hunter Perkins Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400
Closed -$3K – 116
2025
Q2 		$3K Hold
400
– – ﹤0.01% 110
2025
Q1 		$3K Hold
400
– – ﹤0.01% 104
2024
Q4 		$14K Hold
400
– – ﹤0.01% 104
2024
Q3 		$19K Hold
400
– – ﹤0.01% 106
2024
Q2 		$20K Sell
400
-200
-33% -$14.5K ﹤0.01% 107
2024
Q1 		$67K Sell
600
-428
-42% -$42.5K 0.01% 105
2023
Q4 		$60K Sell
1,028
-452
-31% -$18.2K 0.01% 87
2023
Q3 		$47K Buy
+1,480
New +$70.3K 0.01% 124

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hunter Perkins Capital Management's MRSN Position: Q3 2025 in Review

Hunter Perkins Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 400 shares — an estimated $3K sold.

Hunter Perkins Capital Management first reported a position in MRSN in Q3 2023 and held it in 8 quarters. The position peaked at $67K in Q1 2024. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Hunter Perkins Capital Management reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hunter Perkins Capital Management sold 400 Mersana Therapeutics shares in Q3 2025, an estimated $3K.
  • Hunter Perkins Capital Management first reported a position in Mersana Therapeutics in Q3 2023 and held it in 8 quarters.
  • Hunter Perkins Capital Management's Mersana Therapeutics position peaked at $67K in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Hunter Perkins Capital Management's 13F filing for Q3 2025, filed 15 Oct 2025.